首站-论文投稿智能助手
典型文献
An evaluation of safety and survival for patients with locally advanced pancreatic cancer treated with irreversible electroporation combined with chemotherapy: a retrospectively observational study
文献摘要:
Objective::Irreversible electroporation (IRE) is emerging as a new therapy for locally advanced pancreatic cancer (LAPC). We aimed to conduct survival and safety analyses in LAPC patients after treatment with IRE combined with chemotherapy.Methods::A total of 64 patients with LAPC who had received IRE and chemotherapy were retrospectively collected from August 2015 to March 2019 at Sun Yat-sen University Cancer Center. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier method and compared by the log-rank test. A multivariate Cox regression model was used to determine the prognostic factors of survival. The perioperative complications of IRE were also evaluated. The study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (approval No. C2021-003).Results::The median survival of all included patients were 24.63 (95% confidence interval: 21.78-27.49) for overall survival and 13.00 (95% confidence interval: 8.81-17.19) months for progression-free survival, with 96.8%, 51.9%, 18.3%; and 52.3%, 21.5%, 7.9% as the 1-, 2-and 3-year OS and PFS rates, respectively. Tumor size [OS, hazard ratio (HR)=1.768, P= 0.048; PFS, HR= 0.304, P= 0.010], neoadjuvant chemotherapy (OS, HR= 0.338, P= 0.030; PFS, HR= 0.358, P= 0.034), carbohydrate antigen 19-9 variation after IRE (OS, HR= 19.320, P= 0.003; PFS, HR= 14.591, P= 0.021) and tumor response after neoadjuvant chemotherapy (OS, HR= 8.779, P= 0.033; PFS, HR= 5.562, P= 0.008) were predictive factors of survival in patients with LAPC after IRE. Complications were observed in 20.3% of patients. Grade B pancreatic fistula was the most common complication. The complication rates of the late treatment group (6.1%) were significantly lower than those of the first 15 patients after IRE treatment (66.7%). The median length of hospital stay of late treatment group was 8.6 days, which was also shorter than that of the early treatment group (10.0 days).Conclusions::IRE combined with chemotherapy could improve survival of LAPC patients with acceptable complication rates. Therefore, it may be a suitable method for LAPC but should be validated in prospective randomized trials.
文献关键词:
Chemotherapy;Efficacy;Irreversible electroporation;Locally advanced pancreatic cancer;Safety
作者姓名:
He Chaobin;Wang Jun;Mao Yize;Lao Xiangming;Li Shengping
作者机构:
Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China
引用格式:
[1]He Chaobin;Wang Jun;Mao Yize;Lao Xiangming;Li Shengping-.An evaluation of safety and survival for patients with locally advanced pancreatic cancer treated with irreversible electroporation combined with chemotherapy: a retrospectively observational study)[J].胰腺病学杂志(英文),2022(01):27-35
A类:
C2021
B类:
An,evaluation,safety,survival,patients,locally,advanced,pancreatic,cancer,treated,irreversible,electroporation,combined,chemotherapy,retrospectively,observational,study,Objective,Irreversible,IRE,emerging,new,LAPC,We,aimed,conduct,analyses,after,treatment,Methods,total,who,had,received,were,collected,from,August,March,Sun,Yat,sen,University,Cancer,Center,Overall,OS,progression,free,PFS,evaluated,using,Kaplan,Meier,method,compared,by,log,rank,test,multivariate,Cox,regression,model,was,used,determine,prognostic,factors,perioperative,complications,also,approved,Institutional,Review,Board,approval,No,Results,median,included,confidence,interval,overall,months,year,rates,respectively,Tumor,size,hazard,neoadjuvant,carbohydrate,antigen,variation,tumor,response,predictive,Complications,observed,Grade,fistula,most,common,late,group,significantly,lower,than,those,first,length,hospital,stay,days,which,shorter,that,early,Conclusions,could,improve,acceptable,Therefore,may,be,suitable,but,should,validated,prospective,randomized,trials,Chemotherapy,Efficacy,Locally,Safety
AB值:
0.483482
相似文献
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai;Meng Wang;Ting Deng;Yuxian Bai;Kai Zang;Zhanhui Miao;Wenlin Gai;Liangzhi Xie;Yi Ba-Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medical Oncology,Henan Cancer Hospital,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Oncology Department,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Sinocelltech Ltd.,Beijing 100176,China;Beijing Engineering Research Center of Protein and Antibody,Beijing 100176,China;Cell Culture Engineering Center,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China
Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China
Chunli Zhang;Wei Wan;Shuai Zhang;Jingwen Wang;Ru Feng;Jiangtao Li;Junyue Chai;Hebing Zhou;Liru Wang;Yuping Zhong;Xiaodong Mo;Mengzhu Shen;Hongmei Jing;Hui Liu-Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Hematology,Beijing No.6 Hospital,Beijing 100007,China;Department of Hematology,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Department of Hematology,Fuxing Hospital,Capital Medical University,Beijing 100038,China;Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100043,China;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Duo Zuo;Yongzi Chen;Xinwei Zhang;Zhuozhi Wang;Wenna Jiang;Fan Tang;Runfen Cheng;Yi Sun;Lu Sun;Li Ren;Rui Liu-Department of Clinical Laboratory;Department of Tumor Cell Biology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Biomedical Engineering,Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
Prognostic nomogram incorporating radiological features for predicting overall survival in patients with AIDS-related non-Hodgkin lymphoma
Li Xueqin;Pan Ziang;Wang Xing;Hu Tianli;Ye Wen;Jiang Dongmei;Shen Wen;Liu Jinxin;Shi Yuxin;Xia Shuang;Li Hongjun-Radiological Department, Beijing You'an Hospital Affiliated of Capital Medical University, Beijing 100069, China;Neurological Department, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Radiological Department, The Eighth People's Hospital of Guangzhou, Guangzhou, Guangdong 510060, China;Radiological Department, Shanghai Public Health Clinical Center, Affiliated of Fudan University, Shanghai 201058, China;Radiation Department, Tianjin First Central Hospital, Tianjin 300170, China;Radiological Department, Tianjin First Central Hospital, Tianjin 300192, China
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu-Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China;Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China;Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China;Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study
Sun Juxian;Liu Chang;Shi Jie;Wang Nanya;Jiang Dafeng;Mao Feifei;Gu Jingwen;Zhou Liping;Shen Li;Yee Lau Wan;Cheng Shuqun-Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Integrative Oncology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Outpatient Department, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Oncology, First Hospital of Jilin University, Changchun, Jilin 130000, China;Department of Oncology Zhejiang Sian International Hospital, Jiaxing, Zhejiang 314000, China;Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200040, China;Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR 999077, China
Hepatopancreatoduodenectomy for advanced biliary malignancies
Wu Xiangsong;Li Maolan;Wu Wenguang;Wang Xu’an;Li Huaifeng;Bao Runfa;Shu Yijun;Shen Jun;Gu Jun;Wang Xuefeng;Gong Wei;Peng Shuyou;Liu Yingbin-Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China;Shanghai Research Center of Biliary Tract Disease, Shanghai 200092, China;Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;State Key Laboratory of Oncogenes and Related Genes, Shanghai 200092, China;Department of General Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejing 310009, China
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Changlong Li;Zhen Guan;Yi Zhao;Tingting Sun;Zhongwu Li;Weihu Wang;Zhexuan Li;Lin Wang;Aiwen Wu-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiation Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。